US 11,938,343 B2
Cavitation-enhanced targeted drug delivery and dosing
Yoav Levy, Hinanit (IL); and Kobi Vortman, Haifa (IL)
Assigned to INSIGHTEC, LTD., Tirat Carmel (IL)
Appl. No. 16/622,005
Filed by INSIGHTEC, LTD., Tirat Carmel (IL)
PCT Filed Jun. 29, 2018, PCT No. PCT/IB2018/000811
§ 371(c)(1), (2) Date Dec. 12, 2019,
PCT Pub. No. WO2019/002940, PCT Pub. Date Jan. 3, 2019.
Application 16/622,005 is a continuation in part of application No. 15/637,163, filed on Jun. 29, 2017, granted, now 11,123,575.
Claims priority of provisional application 62/526,548, filed on Jun. 29, 2017.
Claims priority of provisional application 62/526,545, filed on Jun. 29, 2017.
Claims priority of provisional application 62/526,550, filed on Jun. 29, 2017.
Claims priority of provisional application 62/597,073, filed on Dec. 11, 2017.
Claims priority of provisional application 62/597,076, filed on Dec. 11, 2017.
Prior Publication US 2021/0146157 A1, May 20, 2021
Int. Cl. A61N 7/02 (2006.01); A61B 5/00 (2006.01); A61B 34/10 (2016.01); A61M 37/00 (2006.01); A61N 5/10 (2006.01); A61N 7/00 (2006.01); A61B 6/00 (2006.01); A61B 6/03 (2006.01); A61B 6/12 (2006.01)
CPC A61N 5/1049 (2013.01) [A61B 5/489 (2013.01); A61B 34/10 (2016.02); A61M 37/0092 (2013.01); A61N 5/103 (2013.01); A61N 5/1039 (2013.01); A61N 5/1048 (2013.01); A61N 5/1064 (2013.01); A61N 7/02 (2013.01); A61B 5/4836 (2013.01); A61B 6/03 (2013.01); A61B 6/12 (2013.01); A61B 6/504 (2013.01); A61N 2005/1052 (2013.01); A61N 2005/1055 (2013.01); A61N 2005/1058 (2013.01); A61N 2005/1061 (2013.01); A61N 2005/1087 (2013.01); A61N 2005/1092 (2013.01); A61N 2005/1098 (2013.01); A61N 2007/0004 (2013.01); A61N 2007/0039 (2013.01); A61N 2007/0052 (2013.01); A61N 2007/0082 (2013.01); A61N 2007/027 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A system for causing a disruption of a target tissue for treatment and evaluating the disruption of the target tissue, the system comprising a controller configured to:
prior to causing the disruption of the target tissue, cause an imaging device to acquire a digital representation of at least a portion of a target volume of the target tissue;
cause the disruption of the target tissue in a region corresponding to the target volume by causing an ultrasound transducer to generate and deliver at least one sonication of shaped energy beams to the target volume so as to increase tissue permeability therein;
subsequent to causing the disruption of the target tissue, generate a tissue permeability map indicating regions of increased tissue permeability and estimates of the tissue permeability due to the disruption of the target tissue and computationally evaluate, based on the tissue permeability map, the disruption of the target tissue within the target volume;
compare (i) a mapped region of the tissue permeability map having increased permeability due to the disruption of the target tissue to (ii) the digital representation of the target volume acquired using the imaging device prior to causing the disruption of the target tissue; and
determine that a therapeutic agent should be administered into the target volume only when, based on the comparing, there is a substantial match between (i) the mapped region of the tissue permeability map having increased permeability due to the disruption at the target tissue and (ii) the digital representation of the target volume acquired using the imaging device prior to causing the disruption of the target tissue.